Floatz logo

Lmv-12

RET Gene Mutation

Hunan Province Tumor HospitalPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the RET Gene Mutation cohort.

Asset / SponsorPhaseRating
Toripalimab
Guangdong Provincial People's Hospital
Phase 2CCC
Regorafenib
University of California, San Francisco
Phase 2CCC
Carboplatin
Guangdong Provincial People's Hospital
Phase 2CCC
Entrectinib
University of California, San Francisco
Phase 2CCC
Ceritinib
University of California, San Francisco
Phase 2CCC

View all 14 →

Same molecule, other indications

Lmv-12 is also rated in:

EGF-R Positive Non-Small Cell Lung CancerDormant
CCC
Indicative ·
48 / 100
View asset →
MET AmplificationDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →